Effects of drop‐out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia

@article{Hutton2012EffectsOD,
  title={Effects of drop‐out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia},
  author={Paul Hutton and Anthony P Morrison and Angela Yung and Peter J Taylor and Paul French and Graham Dunn},
  journal={Acta Psychiatrica Scandinavica},
  year={2012},
  volume={126}
}
Hutton P, Morrison AP, Yung AR, Taylor PJ, French P, Dunn G. Effects of drop‐out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia. 
Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review.
TLDR
Cognitive-behavioral therapy was associated with robust improvements in the positive symptoms of psychotic disorders and the improvements were sustained at follow-up, the authors reported. Expand
Risperidone versus placebo for schizophrenia.
TLDR
Risperidone appears to be benefitial in improving mental state compared with placebo, but it also has more adverse events than placebo, and many of the included trials have industry sponsorship of involvement. Expand
Quetiapine immediate release v. placebo for schizophrenia: systematic review, meta-analysis and reappraisal
TLDR
Quetiapine IR has a small beneficial effect on overall psychotic symptoms over 2–12 weeks, but also leads to weight gain and sedation, and more conservative assumptions about the outcomes of people who left the trial early were made. Expand
Declining efficacy in controlled trials of antidepressants: effects of placebo dropout.
TLDR
It is proposed that declining placebo-dropout rates ascribed to inefficacy combined with use of LOCF analyses led to increasing improvement in placebo-arms that contributed to declining antidepressant-placebo contrasts in controlled treatment trials since the 1980s. Expand
Should people with psychosis be supported in choosing cognitive therapy as an alternative to antipsychotic medication: A commentary on a commentary
TLDR
A number of arguments he raised in his commentary do not withstand scrutiny and he should be commended for producing world-leading evidence on the effectiveness and safety of alternative approaches, such as cognitive behavioural therapy (CBT). Expand
Number Needed to Harm: Its Limitations in Psychotropic Drug Safety Research
TLDR
The NNH metric supplies very limited information on the risks of psychotropic medication, and postmarketing surveillance of community treatment populations using case-control methodology provides far more useful data on serious ADEs. Expand
Cognitive behavioural therapy for psychosis: rationale and protocol for a systematic review and meta-analysis
Background: Cognitive behavioural therapy (CBT) is a recommended treatment for people with psychosis, with meta-analyses showing important benefits when compared to treatment as usual (TAU). However,Expand
Cognitive-BehavioralTherapyfor Medication-ResistantPsychosis: AMeta-AnalyticReview
Objective: Support for cognitive-behavioral therapy (CBT) for psychosis has accumulated, with several reviews and meta-analyses indicating its effectiveness for various intended outcomes in a broadExpand
RE: Hutton P. et al. Cognitive behavioural therapy for psychosis: rationale and protocol for a systematic review and meta-analysis
Dear Editor In edition 6–3 of this journal Hutton and colleagues (2014) make strong statements about Cochrane schizophrenia reviews in general and one in particular. In general they state “as withExpand
In reply to Adams and colleagues
Dear Editor We disagree with the Cochrane Schizophrenia Group’s (CSzG) self-assessment that the problems we identified (Hutton, Wood, Taylor, Irving & Morrison, 2014) in their reviews of popularExpand
...
1
2
3
...

References

SHOWING 1-10 OF 91 REFERENCES
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6‐month double‐blind controlled clinical trial
TLDR
The aim of the study was to evaluate the efficacy of olanzapine over a 6‐month period in chronic schizophrenic patients experiencing predominantly negative symptoms. Expand
Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal‐related relapse
  • J. Moncrieff
  • Psychology, Medicine
  • Acta psychiatrica Scandinavica
  • 2006
TLDR
The evidence that discontinuation of long‐term antipsychotic medication, including clozapine, may provoke a psychotic episode is examined. Expand
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
TLDR
In people with schizophrenia whose medication is changed for clinical reasons, there is no disadvantage across 1 year in terms of quality of life, symptoms, or associated costs of care in using FGAs rather than nonclozapine SGAs. Expand
Antipsychotic prescribing trends: a review of pharmaco‐epidemiological studies
TLDR
Findings from pharmaco‐epidemiological studies exploring antipsychotic drugs prescribing trends are reviewed to review findings from pharmaceuticals prescribing trends. Expand
Risperidone versus placebo for schizophrenia.
TLDR
Based on low quality evidence, risperidone appears to be benefitial in improving mental state compared with placebo, but it also causes more adverse events and is less likely to leave early compared to placebo group. Expand
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
TLDR
It is concluded that the drug versus placebo difference of SGA drugs and haloperidol in recent trials was moderate, and that there is much room for more efficacious compounds. Expand
Aripiprazole for schizophrenia.
TLDR
Compared with typical antipsychotics there were no significant benefits for aripiprazole with regards to global state, mental state, quality of life or leaving the study early, and the authors contacted relevant pharmaceutical companies, the FDA and authors of trials for additional information. Expand
Risperidone: clinical safety and efficacy in schizophrenia.
TLDR
It is suggested that risperidone may offer a superior side-effect profile, and possibly greater efficacy, than a standard neuroleptic such as haloperidol. Expand
ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia.
TLDR
ICI 204,636 showed efficacy in the positive and negative symptoms of schizophrenia and was well tolerated. Expand
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
TLDR
A meta-analysis of randomised controlled trials to compare the effects of second-generation antipsychotic drugs in patients with schizophrenia provided data for individualised treatment based on efficacy, side-effects, and cost. Expand
...
1
2
3
4
5
...